%0 Journal Article
%T Current and Emerging Therapies in Peripheral T-cell Lymphoma: Focus on Pralatrexate
%A Thanyanan Reungwetwattana
%A Sylvia Jaramillo and Julian R. Molina
%J Clinical Medicine Insights: Therapeutics
%D 2012
%I 
%R 10.4137/CMT.S3778
%X Peripheral T-cell lymphomas (PTCL) represent about 12%¨C15% of non-Hodgkin lymphomas and are characterized for being a molecularly heterogenous group of diseases. The optimal treatment for PTCLs remains to be defined as they are usually refractory to existing therapies and carry a poor prognosis. Pralatrexate (PDX), a rationally designed antifolate drug, was granted FDA approval as a single agent for the treatment of relapsed/refractory PTCL in 2009. Because of its favorable toxicity profile and activity, Pralatrexate has become a major compound for patients with refractory PTCL.
%U http://www.la-press.com/current-and-emerging-therapies-in-peripheral-t-cell-lymphoma-focus-on--article-a2559